HOOK (HOOKIPA Pharma) Accumulated Depreciation: $-1.45 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HOOK HOOKIPA Pharma Inc HOOK
50 GF Score
Price $1.15
View Full Analysis

What is HOOKIPA Pharma Accumulated Depreciation?

HOOKIPA Pharma HOOK 50 Accumulated Depreciation is $-1.45 Mil as of Jun. 2025. GuruFocus rates HOOK with a GF Score™ of 50/100.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

HOOKIPA Pharma's quarterly accumulated depreciation declined from Dec. 2024 ($-5.89 Mil) to Mar. 2025 ($-1.65 Mil) but then stayed the same from Mar. 2025 ($-1.65 Mil) to Jun. 2025 ($-1.45 Mil).

HOOKIPA Pharma's annual accumulated depreciation increased from Dec. 2022 ($-7.78 Mil) to Dec. 2023 ($-9.82 Mil) but then stayed the same from Dec. 2023 ($-9.82 Mil) to Dec. 2024 ($-5.89 Mil).

HOOKIPA Pharma Accumulated Depreciation Related Terms

HOOKIPA Pharma Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for HOOKIPA Pharma's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HOOKIPA Pharma Accumulated Depreciation Chart

HOOKIPA Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accumulated Depreciation
Get a 7-Day Free Trial -5.10 -6.37 -7.78 -9.82 -5.89

HOOKIPA Pharma Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.71 -10.46 -5.89 -1.65 -1.45
HOOK
50GF Score
HOOKIPA Pharma Inc HOOK
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HOOKIPA Pharma Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $-1.45 Mil mean?
HOOKIPA Pharma (HOOK) has a Accumulated Depreciation of $-1.45 Mil as of Jun. 2025. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on HOOKIPA Pharma and its competitors.
Is HOOKIPA Pharma's Accumulated Depreciation too high?
HOOKIPA Pharma's current Accumulated Depreciation is $-1.45 Mil. Overall, HOOKIPA Pharma has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's Accumulated Depreciation compare to COCP and LNAI?
HOOKIPA Pharma's Accumulated Depreciation of $-1.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on HOOKIPA Pharma and its competitors. HOOKIPA Pharma's current Accumulated Depreciation is $-1.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
HOOKIPA Pharma (HOOK) has a current Accumulated Depreciation of $-1.45 Mil. The current Accumulated Depreciation is $-1.45 Mil. HOOKIPA Pharma's overall GF Score™ is 50/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current Accumulated Depreciation is $-1.45 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HOOKIPA Pharma Business Description

Address 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
50GF Score

Get the complete analysis for HOOK

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.15
Price